Ophthotech Corp Cmn (OPHT) 64.42 $OPHT Ophthotech

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Ophthotech Corp Cmn (OPHT) 64.42 $OPHT

Ophthotech Corporation to Report Second Quarter 2016 Financial Results and Host Conference Call on Wednesday, August 3, 2016
BusinessWire - Mon Jul 25, 6:30AM CDT
Ophthotech Corporation (Nasdaq: OPHT) today announced that it will report its second quarter 2016 financial results on Wednesday, August 3, 2016. Following the announcement, Ophthotech's management team will host a live conference call and webcast at 8:00 a.m. Eastern Time to discuss the Company's financial results and provide a general business update.
OPHT: 64.42 (+0.18)

Ophthotech Corporation to Present at the Goldman Sachs 37th Annual Global Healthcare Conference
BusinessWire - Tue May 31, 6:30AM CDT
Ophthotech Corporation (NASDAQ:OPHT) announced today that David R. Guyer, M.D., Chief Executive Officer and Chairman of the Board, will present at the Goldman Sachs 37th Annual Global Healthcare Conference in Rancho Palos Verdes, California on Tuesday June 7, 2016 at 8:40 a.m. PT (11:40 a.m. ET).
OPHT: 64.42 (+0.18)

What to Look for in These Biotech Stocks? Threshold Pharma, Seattle Genetics, Chiasma, and Ophthotech
PR Newswire - Wed May 18, 7:38AM CDT
The Biotech industry continues to face a wave of challenges, but it does not mean that there are no opportunities ahead. Today, ActiveWallSt.com has on its list these four equities: Threshold Pharmaceuticals Inc. (NASDAQ: THLD), Seattle Genetics Inc. (NASDAQ: SGEN), Chiasma Inc. (NASDAQ: CHMA), and Ophthotech Corp. (NASDAQ: OPHT). Sign up now to receive our free insights and trading alerts at:
SGEN: 49.22 (+1.16), OPHT: 64.42 (+0.18), THLD: 0.50 (-0.01), CHMA: 2.70 (+0.05)

pSivida CEO to Present at 2016 International Symposium of Ocular Pharmacology and Therapeutics
GlobeNewswire - Wed May 04, 7:00AM CDT
pSivida Corp. (NASDAQ SDV) (ASX VA), a leader in the development of sustained release drug delivery products for treating eye diseases, today announced that Dr. Paul Ashton, president and CEO, will present "Changing the Treatment Paradigm through Innovative Drug Delivery" at the International Symposium of Ocular Pharmacology and Therapeutics (ISOPT) on Sunday, May 8, 2016 in Paris.
OPHT: 64.42 (+0.18), PSDV: 3.93 (+0.11), PVA: 0.15 (-0.04)

Ophthotech reports 1Q loss
Automated Insights - Wed May 04, 6:38AM CDT
NEW YORK (AP) _ Ophthotech Corp. (OPHT) on Wednesday reported a first-quarter loss of $36.3 million, after reporting a profit in the same period a year earlier.
OPHT: 64.42 (+0.18)

Ophthotech Reports First Quarter 2016 Financial and Operating Results
BusinessWire - Wed May 04, 6:30AM CDT
Ophthotech Corporation (Nasdaq:OPHT) today announced financial results for the first quarter ended March 31, 2016 and provided an update on the Company's business and product development programs.
OPHT: 64.42 (+0.18)

Will AVEO Pharmaceuticals (AVEO) Surprise in Q1 Earnings?
Zacks Equity Research - Zacks Investment Research - Tue May 03, 5:42PM CDT
AVEO Pharmaceuticals (AVEO) is expected to report first-quarter 2016 results on Mar 5.
ZTS: 50.40 (-0.07), OPHT: 64.42 (+0.18), AVEO: 0.99 (-0.01), NVS: 83.07 (-0.19)

Ophthotech Corporation to Report First Quarter 2016 Financial Results and Host Conference Call on Wednesday, May 4, 2016
BusinessWire - Tue Apr 26, 6:30AM CDT
Ophthotech Corporation (Nasdaq:OPHT) today announced that it will report its first quarter 2016 financial results on Wednesday, May 4, 2016. Following the announcement, Ophthotech's management team will host a live conference call and webcast at 8:00 a.m. Eastern Time to discuss the Company's financial results and provide a general business update.
OPHT: 64.42 (+0.18)

AVEO Gives AV-203 Ex-U.S. Rights to CANbridge Life Sciences
Zacks Equity Research - Zacks Investment Research - Wed Mar 23, 3:25AM CDT
AVEO Pharmaceuticals (AVEO) struck an exclusive collaboration and license agreement granting CANbridge Life Sciences rights to AV-203 outside North America.
BIIB: 301.83 (+11.90), OPHT: 64.42 (+0.18), AVEO: 0.99 (-0.01), NVS: 83.07 (-0.19)

Ophthotech Corporation to Present at Barclays Global Healthcare Conference 2016
BusinessWire - Tue Mar 08, 6:30AM CST
Ophthotech Corporation (NASDAQ:OPHT) announced today that David R. Guyer, M.D., Chief Executive Officer and Chairman of the Board, will present an overview of the Company at the Barclays Global Healthcare Conference 2016 in Miami on Tuesday, March 15, 2016 at 10:45 a.m. Eastern Time.
OPHT: 64.42 (+0.18)

Why Ophthotech Corporation Shares Tumbled 31% in January
Todd Campbell, The Motley Fool - Motley Fool - Sat Feb 06, 7:40AM CST
Source: Flickr user Luis Gustavo Zamudio A. W hat: Despite kicking off new trials in dry age-related macular degeneration, shares in Ophthotech Corporation dropped 31% in January, according to S&P Capital IQ. So what: In January,...
OPHT: 64.42 (+0.18), REGN: 434.00 (+8.88), NVS: 83.07 (-0.19)

Ophthotech Corporation to Present at the LEERINK Partners 5th Annual Global Healthcare Conference
BusinessWire - Wed Feb 03, 6:30AM CST
Ophthotech Corporation (NASDAQ:OPHT) announced today that David R. Guyer, M.D., Chief Executive Officer and Chairman of the Board, will present an overview of the Company at the LEERINK Partners 5th Annual Global Healthcare Conference in New York City on Wednesday, February 10, 2016 at 11:05 a.m. Eastern Time.
OPHT: 64.42 (+0.18)

Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review 2015
M2 - Fri Jan 29, 10:04AM CST
Research and Markets (http://www.researchandmarkets.com/research/rfl587/wet_neovascular) has announced the addition of the "Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Wet (Neovascular / Exudative) Macular Degeneration Overview - Therapeutics Development - Pipeline Products for Wet (Neovascular / Exudative) Macular Degeneration - Overview - Pipeline Products for Wet (Neovascular / Exudative) Macular Degeneration - Comparative Analysis - Wet (Neovascular / Exudative) Macular Degeneration - Therapeutics under Development by Companies - Wet (Neovascular / Exudative) Macular Degeneration - Therapeutics under Investigation by Universities/Institutes - Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Wet (Neovascular / Exudative) Macular Degeneration - Products under Development by Companies - Wet (Neovascular / Exudative) Macular Degeneration - Products under Investigation by Universities/Institutes - Wet (Neovascular / Exudative) Macular Degeneration - Companies Involved in Therapeutics Development Companies Mentioned: - Aciont Inc. - Allergan Plc - Amakem NV - Apellis Pharmaceuticals, Inc. - Apexigen, Inc. - Applied Genetic Technologies Corporatio - Avalanche Biotechnologies, Inc. - Benitec Biopharma Limited - BIOCAD - Boehringer Ingelheim GmbH - Charlesson LLC. - Chong Kun Dang Pharmaceutical Corp. - Circadian Technologies Limited - Clanotech AB - Clearside BioMedical, Inc. - Daiichi Sankyo Company, Limited - Eleven Biotherapeutics Inc. - Exonate Limited - F. Hoffmann-La Roche Ltd. - Formycon AG - GTx, Inc. - iCo Therapeutics Inc. - Icon Bioscience, Inc. - Kala Pharmaceuticals, Inc. - Mabion SA - Mitotech S.A. - Neurotech Pharmaceuticals, Inc. - Novartis AG - Ocular Therapeutix, Inc. - Ohr Pharmaceutical Inc. - Ophthotech Corp. - Oxford BioMedica Plc - PanOptica, Inc. - Pfenex Inc. - Pfizer Inc. - Quark Pharmaceuticals, Inc. - Regeneron Pharmaceuticals, Inc. - RegenxBio Inc. - RXi Pharmaceuticals Corporation - Santen Pharmaceutical Co., Ltd. - Sanwa Kagaku Kenkyusho Co., Ltd. - TRACON Pharmaceuticals, Inc. - TWi Pharmaceuticals, Inc. - Tyrogenex, Inc. - Xbrane Bioscience AB For more information visit http://www.researchandmarkets.com/research/rf...eovascular
CLSD: 6.08 (+0.03), PFE: 37.31 (+0.42), OPHT: 64.42 (+0.18), PFNX: 8.60 (+0.53), OCUL: 4.38 (+0.01), AGN: 254.86 (+1.91), GTXI: 0.53 (-0.02), OHRP: 2.73 (unch), AAVL: 4.14 (-0.18), TCON: 5.12 (+0.02), REGN: 434.00 (+8.88), NVS: 83.07 (-0.19)

Ophthotech Announces First Patient Dosed in Zimura(R) Phase 2/3 Study to Evaluate Treatment in Patients with Geographic Atrophy, an Advanced Form of Dry Age-Related Macular Degeneration
BusinessWire - Wed Jan 27, 6:30AM CST
Ophthotech Corporation (Nasdaq:OPHT) announced that the first patient has been dosed in a Phase 2/3 clinical study of Zimura(R) (avacincaptad pegol sodium), an inhibitor of complement factor C5, in patients with geographic atrophy, an advanced form of dry age-related macular degeneration (AMD). Complement factor C5 is a central component of the complement cascade believed to be involved in the development of AMD. The Phase 2/3 randomized, double-masked, controlled trial is designed to evaluate the safety and efficacy of Zimura(R) monotherapy in patients with geographic atrophy. The Company has also recently announced the initiation of a Phase 2 study of Zimura(R) in combination with anti-VEGF therapy in wet AMD patients to potentially reduce the treatment burden.
OPHT: 64.42 (+0.18)

Dry (Atrophic) Macular Degeneration therapeutics Pipeline Review, H2 2015
M2 - Fri Jan 22, 6:00AM CST
Research and Markets (http://www.researchandmarkets.com/research/3cxkl2/dry_atrophic) has announced the addition of the "Dry (Atrophic) Macular Degeneration - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Dry (Atrophic) Macular Degeneration, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dry (Atrophic) Macular Degeneration and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Dry (Atrophic) Macular Degeneration Overview - Therapeutics Development - Pipeline Products for Dry (Atrophic) Macular Degeneration - Overview - Pipeline Products for Dry (Atrophic) Macular Degeneration - Comparative Analysis - Dry (Atrophic) Macular Degeneration - Therapeutics under Development by Companies - Dry (Atrophic) Macular Degeneration - Therapeutics under Investigation by Universities/Institutes - Dry (Atrophic) Macular Degeneration - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Dry (Atrophic) Macular Degeneration - Products under Development by Companies - Dry (Atrophic) Macular Degeneration - Products under Investigation by Universities/Institutes - Dry (Atrophic) Macular Degeneration - Companies Involved in Therapeutics Development - Aciont Inc. - Acucela Inc. - Alexion Pharmaceuticals, Inc. - Alimera Sciences, Inc. - Apellis Pharmaceuticals, Inc. - Benitec Biopharma Limited - Catalyst Biosciences, Inc. - Cell Cure Neurosciences, Ltd. - Foamix Pharmaceuticals Ltd. - Genentech, Inc. - GenSight Biologics SA - GlaxoSmithKline Plc - Icon Bioscience, Inc. - MacuCLEAR, Inc. - Novartis AG - Ocata Therapeutics, Inc. - Ophthotech Corp. - pSivida Corp. - R-Tech Ueno, Ltd. - StemCells, Inc. - Sun Pharma Advanced Research Company Ltd. - U.S. Stem Cell, Inc. For more information visit http://www.researchandmarkets.com/research/3c...y_atrophic
OCAT: 8.47 (+0.01), OPHT: 64.42 (+0.18), FOMX: 8.01 (-0.51), GNST: (), GSK: 45.25 (+0.18), ALIM: 2.08 (+0.03), ALXN: 133.50 (+4.90), CBIO: 1.44 (-0.05), NVS: 83.07 (-0.19)

Why Opthotech Corporation Shares Skyrocketed by 75% in 2015
Todd Campbell, The Motley Fool - Motley Fool - Sun Jan 10, 9:20AM CST
Source: National Eye Institute. W hat:  A new adjunct therapy under development that could improve outcomes for people suffering from a form of age-related vision loss caused shares in  Ophthotech Corporation  to soar higher by 75% in 2015,...
OPHT: 64.42 (+0.18), REGN: 434.00 (+8.88), NVS: 83.07 (-0.19)

Ophthotech Announces Appointment of David E. Redlick to Its Board of Directors
BusinessWire - Wed Jan 06, 3:05PM CST
Ophthotech Corporation (Nasdaq: OPHT) today announced the appointment of David E. Redlick to its Board of Directors effective immediately.
OPHT: 64.42 (+0.18)

Glenn P. Sblendorio to Join Ophthotech as Executive Vice President, Chief Operating Officer and Chief Financial Officer
BusinessWire - Tue Jan 05, 6:30AM CST
Ophthotech Corporation (NASDAQ: OPHT) today announced that Glenn P. Sblendorio, a leading industry veteran, has agreed to join the Company as Executive Vice President, Chief Operating Officer and Chief Financial Officer on April 1, 2016. Mr. Sblendorio is joining Ophthotech from The Medicines Company, where he most recently served as President and Chief Financial Officer. Mr. Sblendorio has more than 30 years of experience in the life sciences sector and is widely known in the investment community and the biotechnology / pharmaceutical industry. He has held a variety of senior management positions at Hoffmann-LaRoche, Inc., Eyetech Pharmaceuticals Inc. and MPM Capital Advisors, LLC. Mr. Sblendorio has served as a member of the Board of Directors and the Audit Committee Chairman of Ophthotech. He will resign as a Director of Ophthotech effective with the assumption of his new executive position, and effective immediately, Mr. Sblendorio will no longer serve on the Audit Committee. Ophthotech also announced today that Michael G. Atieh is retiring as Executive Vice President and Chief Financial and Business Officer of the Company. The Company expects that Mr. Atieh's retirement will be effective as of April 1, 2016.
OPHT: 64.42 (+0.18)

Ophthotech Corporation to Present at the 34th Annual J.P. Morgan Healthcare Conference
BusinessWire - Mon Jan 04, 3:05PM CST
Ophthotech Corporation (NASDAQ: OPHT) announced today that David R. Guyer, M.D., Chief Executive Officer and Chairman of the Board, will present an overview of the Company at the 34th Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 11, 2016 at 2:30 p.m. Pacific Time (5:30 p.m. Eastern Time).
JPM: 63.80 (-0.17), OPHT: 64.42 (+0.18)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Vail’s Board Fight Puts Strategy Under a Sharp Lens

Updated Category News Views 62

Fresh snow does not make a boardroom dispute disappear. Vail Resorts has put out an investor presentation ahead of its December 14, 2026 annual meeting, asking shareholders to support all nine of management’s director nominees on its white proxy card. That is the formal message. The real message is plainer: NYSE:MTN knows this election has become a test of whether...

Continue Reading
Color Me Mine Tests Florida's Creative Leisure Demand

Updated Category News Views 72

Pottery studios are not exactly the sort of thing that makes markets pound the table, but Florida’s latest Color Me Mine push deserves a closer look. The company signed three franchise agreements in 2026 for Panama City Beach, Doral and Boca Raton, adding planned growth to a state where it already operates 11 studios. For a private franchisor, this is not a quarterly...

Continue Reading
Peptide Labels Cannot Substitute for Clinical Care

Updated Category News Views 151

A Label Is Not a Care Plan Those three little words, research use only, carry far more weight than a flashy product page would have people believe. The HelloNation article featuring wellness expert Andres Giraldo makes a plain but necessary distinction: a research-use-only, or RUO, label does not turn a peptide into prescribed treatment, and it sure does not establish...

Continue Reading
Somerville’s New Immersive Bet Has Room to Grow Locally

Updated Category News Views 74

A passcard, a hidden door, and 12,000 square feet of mischief have landed at Somernova. Edge of Elsewhere, the new flagship attraction from Boston-area creative studio Midnight Mansion, is open in Somerville’s Union Square as of November 18, 2026. It is part interactive art installation, part puzzle game, part physical story world. That sounds delightfully odd, which is...

Continue Reading
Watson Motion Tests Military Pretrial Confinement Rules

Updated Category News Views 170

Military confinement fights are rarely neat, and this one comes with a short clock but plenty of unanswered questions. Defense lawyers for U.S. Air Force Maj. Jason Watson argued on Nov. 17 that he should be released from pretrial confinement while his case proceeds. A military judge is ordinarily expected to issue a ruling within 14 days of the hearing, under the court's...

Continue Reading
AI Gives CPA Firms a New Advisory Staffing Math Today

Updated Category News Views 75

Month-end just got a lot less comfortable for firms living on the clock. Netsurit and Southwestern Talent are pitching the Virtual CFO Platform as a way for CPA firms to turn machine-led analysis into advisory work without first building a costly bench of specialists. That is not a cute workflow tweak. It goes straight at the labor model that has kept plenty of accounting...

Continue Reading
Hanmi Compressor Tests Vietnam Before Wider Expansion

Updated Category News Views 175

Compressed air is the sort of factory necessity nobody brags about until it fails, and that is precisely why Hanmi Compressor’s Vietnam plan deserves a sober look. The Daegu-based specialist is not arriving with a grand export victory lap. It is still building the front door: a website, a promotional video, and a process for finding Vietnamese manufacturers and...

Continue Reading
Hitachi's Quiet Fusion Bet Is Really About Data Control

Updated Category News Views 69

Weeks of engineering work can vanish because one storage system hiccups, which is a rotten way to learn that data infrastructure belongs in the mission-critical column. Esteyco’s new environment, built with Hitachi Vantara and implemented by Quadrics Sistemas, is not a fusion breakthrough. It is the less glamorous machinery that keeps serious fusion research from...

Continue Reading
Emaar's Huspy Deal Brings Financing Into Home Sales

Updated Category News Views 87

Mortgage paperwork is nobody’s idea of luxury, yet it can wreck a property sale faster than a bad floor plan. Emaar Properties has partnered with Dubai-based Huspy to give its customers access to mortgage advice and financing comparisons from more than 20 UAE banks. It is not a flashy tower launch or a headline-grabbing land purchase. Frankly, that is why investors...

Continue Reading
RayNeo's Black Friday Push Tests Smart Glasses Demand

Updated Category News Views 160

A million shipped pairs is a real milestone, but holiday markdowns are where the rubber meets the road for RayNeo. The company is taking its XR gaming glasses and iO AI smart glasses into Europe’s Black Friday scrum with discounts running through late November, betting that portability, giant virtual screens and a little AI convenience can pry open consumers’ wallets....

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring the Growth of SOC-as-a-Service to $14.66 Billion

Updated Category News Views 198

Understanding SOC-as-a-Service Market Growth The global SOC-as-a-Service market is projected to witness substantial growth, anticipated to reach a value of USD 14.66 billion by 2030. This growth surge represents a remarkable increase from USD 7.37 billion and reflects a compound annual growth rate (CAGR) of 12.2% during the period from 2024 to 2030. The surge in demand...

Continue Reading
Revolutionary Anti-Aging Hair Solution Launches for Men

Updated Category News Views 308

Just For Men® Launches Gray Reverse™ Hair Serum In an exciting development for men's grooming, Just For Men® has unveiled its latest innovation, the Gray Reverse™ Hair Serum. This groundbreaking product is designed to help men fight against the signs of aging, specifically graying hair, and play a key role in maintaining their natural appearance. Understanding the...

Continue Reading
Legal Guidance for Lantheus Holdings Investors Amid Class Action

Updated Category News Views 242

Introduction to Lantheus Holdings Lantheus Holdings, Inc. (NASDAQ: LNTH) stands as a significant player in the medical technology sector, specializing in diagnostic imaging and therapeutic agents. The company focuses on enhancing diagnosis, treatment, and monitoring of various health conditions. As it gears up for a challenging period marked by considerable scrutiny,...

Continue Reading
OpenAI Explores Development of Innovative Web Browser

Updated Category News Views 167

OpenAI Explores Development of Innovative Web Browser OpenAI, the company behind the popular AI chatbot ChatGPT, is taking strategic steps that could reshape the landscape of web browsing. Recently, it has been reported that OpenAI is contemplating the creation of a new web browser that could work harmoniously with its advanced chatbot technologies. This potential...

Continue Reading
Mercedes-Benz Faces Challenges with New FY24 Financial Guidance

Updated Category News Views 355

Mercedes-Benz Updates Fiscal Year 2024 Projections Recently, the Mercedes-Benz Group adjusted its financial outlook for the fiscal year 2024. Despite this reevaluation, Morgan Stanley has chosen to keep its Overweight rating on Mercedes-Benz (OTC: MBGAF) along with a solid price target of EUR 82.00. This decision comes even as the company revised its financial...

Continue Reading